Laurence J. Egan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laurence J. Egan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
William J Sandborn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
2 shared publicationsCatherine J. Huntoon
Mayo Clinic
1 shared publicationD. C. Mays
Clinical Pharmacology Unit
1 shared publicationDavid J. McKean
Mayo Clinic
1 shared publicationDennis C. Mays
Mayo Clinic
1 shared publication- Edward Vincent Loftus
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester, MN
1 shared publication
Latest Publications
- Open Access
- 1 May 2005
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 11 (5) , 428-434
Endoscopic Factors in the Diagnosis of Colorectal Dysplasia in Chronic Inflammatory Bowel Disease
Background. Surveillance colonoscopy in inflammatory bowel diseases (IBDs) is advocated for early diagnosis of neoplasia but is imperfect because some patients
- 1 May 2005
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 11 (5) , 428-434
Open AccessEndoscopic Factors in the Diagnosis of Colorectal Dysplasia in Chronic Inflammatory Bowel Disease
Background. Surveillance colonoscopy in inflammatory bowel diseases (IBDs) is advocated for early diagnosis of neoplasia but is imperfect because some patients
- 1 September 2004
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 2 (9) , 725-730
Drug interactions in gastroenterology: Mechanisms, consequences, and how to avoid
- 1 September 2004
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 2 (9) , 725-730
Drug interactions in gastroenterology: Mechanisms, consequences, and how to avoid
- 1 May 2004
- Published by Elsevier in Gastroenterology
- Vol. 126 (6) , 1574-1581
Advances in the treatment of Crohn’s disease
- 1 May 2004
- Published by Elsevier in Gastroenterology
- Vol. 126 (6) , 1574-1581
Advances in the treatment of Crohn’s disease
- Open Access
- 20 June 2003
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (12) , 1521-1528
CYP2C19 pharmacogenetics in the clinical use of proton‐pump inhibitors for gastro‐oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms
Summary: Background: The rate of metabolic inactivation of proton‐pump inhibitors is determined by polymorphisms of CYP2C19. It is not known if CYP2C19 variant alleles affect responses to proton‐pump inhibitor therapy in gastro‐oesophageal reflux disease (GERD).Aim: To determine if the CYP2C19 genotype is associated with clinical effectiveness of proton‐pump inhibitors during GERD therapy.Methods: GERD patients undergoing ambulatory gastric and oesophageal pH monitoring were genotyped for CYP2C19 polymorphisms.Results: Sixty subjects were enrolled. Forty‐four subjects had two wild‐type alleles, 15 had one variant, and one had two variant CYP2C19 alleles. The presence of a variant allele was significantly associated with a lower odds of gastric acid breakthrough during proton‐pump inhibitor therapy [odds ratio 5.14, 95% confidence interval (CI) 1.17–22.61]. The presence of a variant allele was not associated with a lower odds of significant oesophageal acid exposure (odds ratio 2.50, 95% CI 0.60–10.52), or the occurrence of symptoms (incidence rate ratio 1.06, 95% CI 0.54–2.06).Conclusions: These results indicate that factors other than gastric acid secretion are important determinants of reflux in GERD patients. This suggests that CYP2C19 genotype testing will not be useful in proton‐pump inhibitor therapy of GERD, except perhaps in identifying patients at risk for hypochlorhydria and consequent hypergastrinemia.
- 20 June 2003
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (12) , 1521-1528
Open AccessCYP2C19 pharmacogenetics in the clinical use of proton‐pump inhibitors for gastro‐oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms
Summary: Background: The rate of metabolic inactivation of proton‐pump inhibitors is determined by polymorphisms of CYP2C19. It is not known if CYP2C19 variant alleles affect responses to proton‐pump inhibitor therapy in gastro‐oesophageal reflux disease (GERD).Aim: To determine if the CYP2C19 genotype is associated with clinical effectiveness of proton‐pump inhibitors during GERD therapy.Methods: GERD patients undergoing ambulatory gastric and oesophageal pH monitoring were genotyped for CYP2C19 polymorphisms.Results: Sixty subjects were enrolled. Forty‐four subjects had two wild‐type alleles, 15 had one variant, and one had two variant CYP2C19 alleles. The presence of a variant allele was significantly associated with a lower odds of gastric acid breakthrough during proton‐pump inhibitor therapy [odds ratio 5.14, 95% confidence interval (CI) 1.17–22.61]. The presence of a variant allele was not associated with a lower odds of significant oesophageal acid exposure (odds ratio 2.50, 95% CI 0.60–10.52), or the occurrence of symptoms (incidence rate ratio 1.06, 95% CI 0.54–2.06).Conclusions: These results indicate that factors other than gastric acid secretion are important determinants of reflux in GERD patients. This suggests that CYP2C19 genotype testing will not be useful in proton‐pump inhibitor therapy of GERD, except perhaps in identifying patients at risk for hypochlorhydria and consequent hypergastrinemia.
- Open Access
- 1 September 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (37) , 26448-26453
Inhibition of Interleukin-1-stimulated NF-κB RelA/p65 Phosphorylation by Mesalamine Is Accompanied by Decreased Transcriptional Activity
- 1 September 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (37) , 26448-26453
Open AccessInhibition of Interleukin-1-stimulated NF-κB RelA/p65 Phosphorylation by Mesalamine Is Accompanied by Decreased Transcriptional Activity